Aleeza Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aleeza Khan has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Mahnoor Fatima
Shaheed Ziaur Rahman Medical College, Rajshahi Medical University, Bogura, Bangladesh
2 shared publications - Aiman Tahir
Department of Medicine, Azad Jammu and Kashmir Medical College, Muzaffarabad, AJK, Pakistan
1 shared publication - Amna Abdul Razzaq1 shared publication
- Amna Ramzan1 shared publication
- Aneeza Hameed
Wah Medical College, Wah Cantt, Pakistan
1 shared publication - Areej Imtiaz
Nishtar Medical College, Nishtar Medical University Multan, Pakistan
1 shared publication
Latest Publications
- Open Access
- 7 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3753-3758
From recurrent flank pain to systemic oxalosis: a case of primary hyperoxaluria type 1 requiring dual organ transplantation
Introduction and importance: Primary hyperoxalurias (PH) are rare autosomal recessive inherited disorders that disrupt the metabolism of glyoxylate and oxalate. The most common type, primary hyperoxaluria type 1 (PH1), is caused by a deficiency in the liver enzyme alanine-glyoxylate aminotransferase (AGT), leading to the overproduction and excessive urinary excretion of oxalate. Case presentation: On routine evaluation, the patient presented with deranged renal function and echogenic kidneys. Imaging via KUB X-ray revealed radio-opaque kidney stones, small shrunken kidneys, and nephrocalcinosis, indicating progression to end-stage kidney disease (ESKD). Additional systemic manifestations included increased lumbar bone density and pulmonary fibrosis. Diagnosis was definitively confirmed through elevated 24-hour urinary oxalate levels and genetic screening showing an AGXT gene mutation. This necessitated combined liver–kidney transplantation (CLKT): the liver graft provides the missing AGT enzyme to stop oxalate production, while the kidney graft replaces damaged organs and discontinues chronic dialysis. Clinical discussion: PH1 must be suspected in pediatric patients presenting with recurrent urolithiasis or nephrocalcinosis, especially in clinical cases of consanguinity. Early interventions – high fluid intake, crystallization inhibitors, and pyridoxine – can help preserve kidney function. For patients reaching ESKD, combined transplantation is the most effective approach to correct the underlying metabolic error and stop oxalate accumulation. Conclusion: This case highlights the diagnostic challenge of PH1, where the initial presentation with flank pain and urinary symptoms may mimic a urinary tract infection, placing the patient at potential risk of urosepsis if misdiagnosed or untreated. CLKT remains the definitive treatment in advanced disease.
- 7 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3753-3758
Open AccessFrom recurrent flank pain to systemic oxalosis: a case of primary hyperoxaluria type 1 requiring dual organ transplantation
Introduction and importance: Primary hyperoxalurias (PH) are rare autosomal recessive inherited disorders that disrupt the metabolism of glyoxylate and oxalate. The most common type, primary hyperoxaluria type 1 (PH1), is caused by a deficiency in the liver enzyme alanine-glyoxylate aminotransferase (AGT), leading to the overproduction and excessive urinary excretion of oxalate. Case presentation: On routine evaluation, the patient presented with deranged renal function and echogenic kidneys. Imaging via KUB X-ray revealed radio-opaque kidney stones, small shrunken kidneys, and nephrocalcinosis, indicating progression to end-stage kidney disease (ESKD). Additional systemic manifestations included increased lumbar bone density and pulmonary fibrosis. Diagnosis was definitively confirmed through elevated 24-hour urinary oxalate levels and genetic screening showing an AGXT gene mutation. This necessitated combined liver–kidney transplantation (CLKT): the liver graft provides the missing AGT enzyme to stop oxalate production, while the kidney graft replaces damaged organs and discontinues chronic dialysis. Clinical discussion: PH1 must be suspected in pediatric patients presenting with recurrent urolithiasis or nephrocalcinosis, especially in clinical cases of consanguinity. Early interventions – high fluid intake, crystallization inhibitors, and pyridoxine – can help preserve kidney function. For patients reaching ESKD, combined transplantation is the most effective approach to correct the underlying metabolic error and stop oxalate accumulation. Conclusion: This case highlights the diagnostic challenge of PH1, where the initial presentation with flank pain and urinary symptoms may mimic a urinary tract infection, placing the patient at potential risk of urosepsis if misdiagnosed or untreated. CLKT remains the definitive treatment in advanced disease.
- Open Access
- 14 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3861-3863
Next-generation antibody–drug conjugates in drug-resistant solid tumors: promise, toxicity, and the emerging challenge of acquired resistance
Drug-resistant solid tumors represent a major challenge in oncology, with resistance mechanisms, including efflux pump overexpression, apoptotic pathway alterations, and adaptive survival signaling, contributing to poor outcomes despite multimodal therapy. Conventional chemotherapy and first-generation antibody–drug conjugates (ADCs), such as ado-trastuzumab emtansine (T-DM1), were limited by non-specific cytotoxicity, heterogeneous drug–antibody ratios, linker instability, and insufficient bystander killing, yielding modest efficacy in heavily pretreated populations. Next-generation ADCs address these shortcomings through site-specific conjugation, advanced cleavable linkers, and novel payloads, such as topoisomerase I inhibitors, enabling robust bystander killing and circumvention of efflux-mediated resistance. Clinically, trastuzumab deruxtecan demonstrated meaningful progression-free survival benefit in HER2-low metastatic breast cancer, while enfortumab vedotin reduced mortality risk in platinum- and immunotherapy-refractory urothelial carcinoma, establishing ADC efficacy across solid tumor histologies. However, significant toxicity concerns persist. Trastuzumab deruxtecan carries a 15.4% incidence of interstitial lung disease, including fatal events, and sacituzumab govitecan is associated with grade 3 or higher neutropenia in approximately 51% of patients. Furthermore, next-generation ADCs are not resistance-proof, with antigen downregulation, payload efflux, and impaired internalization emerging as clinically relevant escape mechanisms. Biomarker-driven patient selection, rigorous toxicity monitoring, and prospective trials addressing resistance will be essential to realizing the full and durable potential of this drug class.
- 14 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3861-3863
Open AccessNext-generation antibody–drug conjugates in drug-resistant solid tumors: promise, toxicity, and the emerging challenge of acquired resistance
Drug-resistant solid tumors represent a major challenge in oncology, with resistance mechanisms, including efflux pump overexpression, apoptotic pathway alterations, and adaptive survival signaling, contributing to poor outcomes despite multimodal therapy. Conventional chemotherapy and first-generation antibody–drug conjugates (ADCs), such as ado-trastuzumab emtansine (T-DM1), were limited by non-specific cytotoxicity, heterogeneous drug–antibody ratios, linker instability, and insufficient bystander killing, yielding modest efficacy in heavily pretreated populations. Next-generation ADCs address these shortcomings through site-specific conjugation, advanced cleavable linkers, and novel payloads, such as topoisomerase I inhibitors, enabling robust bystander killing and circumvention of efflux-mediated resistance. Clinically, trastuzumab deruxtecan demonstrated meaningful progression-free survival benefit in HER2-low metastatic breast cancer, while enfortumab vedotin reduced mortality risk in platinum- and immunotherapy-refractory urothelial carcinoma, establishing ADC efficacy across solid tumor histologies. However, significant toxicity concerns persist. Trastuzumab deruxtecan carries a 15.4% incidence of interstitial lung disease, including fatal events, and sacituzumab govitecan is associated with grade 3 or higher neutropenia in approximately 51% of patients. Furthermore, next-generation ADCs are not resistance-proof, with antigen downregulation, payload efflux, and impaired internalization emerging as clinically relevant escape mechanisms. Biomarker-driven patient selection, rigorous toxicity monitoring, and prospective trials addressing resistance will be essential to realizing the full and durable potential of this drug class.
- Open Access
- 9 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 1206-1208
JAK inhibitors in toxic epidermal necrolysis a new frontier in therapeutics
- 9 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 1206-1208
Open AccessJAK inhibitors in toxic epidermal necrolysis a new frontier in therapeutics
- Open Access
- 28 August 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (10) , 6256-6258
Acoltremon and the TRPM8 frontier: a new chapter in dry eye disease therapy
- 28 August 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (10) , 6256-6258
Open AccessAcoltremon and the TRPM8 frontier: a new chapter in dry eye disease therapy